Bomyntra®▼

(Denosumab)

For Republic of Ireland healthcare professionals only. This content contains promotional and brand information.

 

Scroll down for Bomyntra prescribing information and further product details. For adverse event reporting see bottom of webpage.

Bomyntra 120 mg solution for injection in vial. Each vial contains 120 mg of denosumab in 1.7 mL of solution (70 mg/mL).


Bomyntyra 120 mg solution for injection in pre-filled syringe.
Each pre-filled syringe contains 120 mg of denosumab in 1.7 mL of solution (70 mg/mL).

For the Republic of Ireland, the SmPC and Patient Leaflets are located on the Medicines.ie | Reliable & Accurate Online Medicines Information (medicines.ie)

Note: by clicking the link you will leave the Fresenius Kabi Ireland website and be directed to the medicines.ie website.

Please note that product images are for illustrative purposes only and labelling on products may appear differently.

Product Image Sizing FK website - bomyntra
Filename
Bomyntra® Prescribing Information.pdf
Size
238 KB
Format
pdf
Bomyntra® Prescribing Information.pdf

Details

Below are the therapeutic indications for Bomymtra 120 mg solution for injection in vial and Bomyntra 120 mg solution for injection in pre-filled syringe.

Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.

Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.   

Adverse events should be reported.
Reporting forms and information can be found at:
www.hpra.ie/homepage/about-us/report-an-issue
Adverse events should also be reported to Fresenius Kabi Limited, Cestrian Court, Eastgate Way, Manor Park, Runcorn, Cheshire, WA7 1NT Tel +44 (0) 800 090 2513

Job code: IE-BOM-2600002

Date of preparation: April 2026

This is intended for healthcare professionals in the Republic of Ireland only and contains information about Fresenius Kabi medicines. By accessing this information you are confirming you are a healthcare professional in the Republic of Ireland.

If you are a healthcare professional based in Northern Ireland please access the Fresenius Kabi UK site here for more information. www.fresenius-kabi.com/gb

If you are not a healthcare professional, please return to the Fresenius Kabi Ireland homepage where you can find more information for the public and for patients using Fresenius Kabi medicines or products.

IE-NP-2400056 November 2024